BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS

• Main Authors: BUNNAGE, MARK EDWARD, LOWE, MICHAEL DENNIS, LEE, ARTHUR, LOVERING, FRANK ELDRIDGE, PATNY, AKSHAY, SAIAH, EDDINE, PAPAIOANNOU, NIKOLAOS, ZAPF, CHRISTOPH WOLFGANG, LEE, KATHERINE LIN, PIERCE, BETSY SUSAN, VARGAS, RICHARD, TRZUPEK, JOHN DAVID, GOLDBERG, JOEL ADAM, HAN, SEUNGIL, HUANG, HORNGIH, HEPWORTH, DAVID, MATHIAS, JOHN PAUL, WANG, XIAOLUN, ANDERSON, DAVID RANDOLPH, STROHBACH, JOSEPH WALTER, GAVRIN, LORI KRIM, WRIGHT, STEPHEN WAYNE, CURRAN, KEVIN JOSEPH, DEHNHARDT, CHRISTOPH MARTIN
• Format: Patent
• Language: English; Polish
• Published: 16.05.2022
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula,as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment of autoimmune and inflammatory diseases associated with Interleukin-1 Receptor Associated Kinase (IRAK), methods of synthesis, and intermediates are also disclosed.